The disease characteristics of PCa, with high incidence, long latency, the availability of tumor markers (prostate-specific antigen (PSA)), heterogeneous risk groups, and the presence of pre-neoplastic lesions, make PCa suitable for chemoprevention by soy and other nutraceuticals [9]. The gene discussed is KLK3; the disease is posterior cortical atrophy.